507 related articles for article (PubMed ID: 31122893)
61. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Sakamoto S; Kataoka K; Kondoh Y; Kato M; Okamoto M; Mukae H; Bando M; Suda T; Yatera K; Tanino Y; Kishaba T; Hattori N; Taguchi Y; Saito T; Nishioka Y; Kuwano K; Kishi K; Inase N; Sasaki S; Takizawa H; Johkoh T; Sakai F; Homma S;
Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703779
[TBL] [Abstract][Full Text] [Related]
62. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Costabel U; Albera C; Glassberg MK; Lancaster LH; Wuyts WA; Petzinger U; Gilberg F; Kirchgaessler KU; Noble PW
Respir Res; 2019 Mar; 20(1):55. PubMed ID: 30866942
[TBL] [Abstract][Full Text] [Related]
63. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
64. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.
Richeldi L; Kreuter M; Selman M; Crestani B; Kirsten AM; Wuyts WA; Xu Z; Bernois K; Stowasser S; Quaresma M; Costabel U
Thorax; 2018 Jun; 73(6):581-583. PubMed ID: 28993537
[TBL] [Abstract][Full Text] [Related]
65. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
66. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
[TBL] [Abstract][Full Text] [Related]
67. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
70. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Kreuter M; Wuyts W; Renzoni E; Koschel D; Maher TM; Kolb M; Weycker D; Spagnolo P; Kirchgaessler KU; Herth FJ; Costabel U
Lancet Respir Med; 2016 May; 4(5):381-9. PubMed ID: 27050871
[TBL] [Abstract][Full Text] [Related]
71. A Phase IIb Randomized Clinical Study of an Anti-α
Raghu G; Mouded M; Chambers DC; Martinez FJ; Richeldi L; Lancaster LH; Hamblin MJ; Gibson KF; Rosas IO; Prasse A; Zhao G; Serenko M; Novikov N; McCurley A; Bansal P; Stebbins C; Arefayene M; Ibebunjo S; Violette SM; Gallagher D; Behr J
Am J Respir Crit Care Med; 2022 Nov; 206(9):1128-1139. PubMed ID: 35771569
[No Abstract] [Full Text] [Related]
72. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
73. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
74. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
[TBL] [Abstract][Full Text] [Related]
75. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
Richeldi L; Azuma A; Cottin V; Kreuter M; Maher TM; Martinez FJ; Oldham JM; Valenzuela C; Gordat M; Liu Y; Stowasser S; Zoz DF; Wijsenbeek MS
BMJ Open Respir Res; 2023 Aug; 10(1):. PubMed ID: 37597969
[TBL] [Abstract][Full Text] [Related]
76. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM; Ford P; Brown KK; Costabel U; Cottin V; Danoff SK; Groenveld I; Helmer E; Jenkins RG; Milner J; Molenberghs G; Penninckx B; Randall MJ; Van Den Blink B; Fieuw A; Vandenrijn C; Rocak S; Seghers I; Shao L; Taneja A; Jentsch G; Watkins TR; Wuyts WA; Kreuter M; Verbruggen N; Prasad N; Wijsenbeek MS;
JAMA; 2023 May; 329(18):1567-1578. PubMed ID: 37159034
[TBL] [Abstract][Full Text] [Related]
77. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
[TBL] [Abstract][Full Text] [Related]
78. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
Maher TM; Costabel U; Glassberg MK; Kondoh Y; Ogura T; Scholand MB; Kardatzke D; Howard M; Olsson J; Neighbors M; Belloni P; Swigris JJ
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33008934
[TBL] [Abstract][Full Text] [Related]
79. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
[TBL] [Abstract][Full Text] [Related]
80. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
